Cargando…

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom

PURPOSE: To describe the use of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark, Sweden, and the United Kingdom (UK). METHODS: We identified new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium aged 18 years or older from the Danish National Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margulis, Andrea V., Linder, Marie, Arana, Alejandro, Pottegård, Anton, Berglind, Ina Anveden, Bui, Christine L., Kristiansen, Nina Sahlertz, Bahmanyar, Shahram, McQuay, Lisa J., Atsma, Willem Jan, Appenteng, Kwame, D'Silva, Milbhor, Perez-Gutthann, Susana, Hallas, Jesper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160033/ https://www.ncbi.nlm.nih.gov/pubmed/30260993 http://dx.doi.org/10.1371/journal.pone.0204456

Ejemplares similares

Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study
por: Arana, Alejandro, et al.
Publicado: (2018)

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
por: Hoffman, Veena, et al.
Publicado: (2021)

Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias
por: Kaye, James A., et al.
Publicado: (2017)

Ophthalmic nepafenac use in the Netherlands and Denmark
por: Margulis, Andrea V, et al.
Publicado: (2017)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
por: Löfling, Lukas, et al.
Publicado: (2019)

Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom
por: Arana, Alejandro, et al.
Publicado: (2020)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Replication of Mini-Sentinel Study Assessing Mirabegron and Cardiovascular Risk in Non-Mini-Sentinel Databases
por: Simeone, Jason C., et al.
Publicado: (2017)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
por: Athanasopoulos, Anastasios, et al.
Publicado: (2011)

Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom
por: Margulis, Andrea V., et al.
Publicado: (2018)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
por: Chughtai, Bilal, et al.
Publicado: (2008)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
por: Andretta, Elena, et al.
Publicado: (2022)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
por: Lee, Soyon, et al.
Publicado: (2009)

Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
por: Parise, Hélène, et al.
Publicado: (2019)

Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
por: Wani, Mudassir M., et al.
Publicado: (2021)

Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population
por: Johnson, Theodore M., et al.
Publicado: (2022)

Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach
por: Kessler, Thomas M., et al.
Publicado: (2011)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
por: Kosilov, Kirill, et al.
Publicado: (2013)

Antimuscarinic Agent Treatment Affecting Patient-Reported Outcomes in Overactive Bladder Syndrome With Depressive Symptoms
por: Kim, Kyu Shik, et al.
Publicado: (2016)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries
por: Aparasu, Rajender R., et al.
Publicado: (2020)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
por: Kuo, Yuh-Chen, et al.
Publicado: (2021)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
por: Arlandis-Guzman, Salvador, et al.
Publicado: (2011)

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
por: Zinner, N, et al.
Publicado: (2008)

Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
por: Liu, Hsin-Tzu, et al.
Publicado: (2013)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
por: Nazir, Jameel, et al.
Publicado: (2018)

Congenital Malformations in Denmark: Considerations for the Use of Danish Health Care Registries
por: Broe, Anne, et al.
Publicado: (2020)

A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study)
por: Castellsague, Jordi, et al.
Publicado: (2018)

Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study
por: Kuiper, Josephina G., et al.
Publicado: (2018)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
por: Campbell, Jonathan D, et al.
Publicado: (2009)

Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors
por: Kosilov, Kirill Vladimirovich, et al.
Publicado: (2017)

Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting
por: Huang, Chiung-Kun, et al.
Publicado: (2020)

Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis
por: Yang, Nannan, et al.
Publicado: (2021)

Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome
por: Xia, Liping, et al.
Publicado: (2021)

Use of Antimuscarinics in the Elderly
por: Patel, Bhavin, et al.
Publicado: (2009)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
por: Hsiao, Sheng-Mou, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3ou0vn1r8a7ml5lujssn6oq2gj